172 related articles for article (PubMed ID: 31039049)
1. Current and emerging biologics for the treatment of hemophilia.
Castaman G; Linari S
Expert Opin Biol Ther; 2019 Aug; 19(8):801-810. PubMed ID: 31039049
[TBL] [Abstract][Full Text] [Related]
2. New therapies using nonfactor products for patients with hemophilia and inhibitors.
Nogami K; Shima M
Blood; 2019 Jan; 133(5):399-406. PubMed ID: 30559263
[TBL] [Abstract][Full Text] [Related]
3. Emicizumab for the prevention of bleeds in hemophilia A.
Mahlangu J
Expert Opin Biol Ther; 2019 Aug; 19(8):753-761. PubMed ID: 31150297
[No Abstract] [Full Text] [Related]
4. Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement.
Santagostino E; Mancuso ME; Novembrino C; Solimeno LP; Tripodi A; Peyvandi F
Haematologica; 2019 Aug; 104(8):e380-e382. PubMed ID: 30923092
[No Abstract] [Full Text] [Related]
5. Evaluating the safety of emicizumab in patients with hemophilia A.
Langer AL; Etra A; Aledort L
Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521
[TBL] [Abstract][Full Text] [Related]
6. Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A.
Lippi G; Favaloro EJ
Adv Clin Chem; 2019; 88():151-167. PubMed ID: 30612605
[TBL] [Abstract][Full Text] [Related]
7. Hemophilia in a Changing Treatment Landscape.
Pelland-Marcotte MC; Carcao MD
Hematol Oncol Clin North Am; 2019 Jun; 33(3):409-423. PubMed ID: 31030810
[TBL] [Abstract][Full Text] [Related]
8. Emicizumab for hemophilia A with factor VIII inhibitors.
Young G; Callaghan M; Dunn A; Kruse-Jarres R; Pipe S
Expert Rev Hematol; 2018 Nov; 11(11):835-846. PubMed ID: 30278802
[TBL] [Abstract][Full Text] [Related]
9. Safety of recombinant coagulation factors in treating hemophilia.
Morfini M; Rapisarda CAP
Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
[TBL] [Abstract][Full Text] [Related]
10. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
Díaz-Ricart M; Isola IM; Escolar G
Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
[TBL] [Abstract][Full Text] [Related]
11. Emicizumab: A Review in Haemophilia A.
Blair HA
Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
[TBL] [Abstract][Full Text] [Related]
12. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
[TBL] [Abstract][Full Text] [Related]
13. Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding.
Hoffman M
Blood Adv; 2021 Sep; 5(18):3736. PubMed ID: 34581771
[TBL] [Abstract][Full Text] [Related]
14. Investigational drugs to treat hemophilia.
Franchini M; Marano G; Pati I; Veropalumbo E; Vaglio S; Pupella S; Masiello F; Cruciani M; Mengoli C; Liumbruno GM
Expert Opin Investig Drugs; 2020 Mar; 29(3):295-301. PubMed ID: 32008381
[No Abstract] [Full Text] [Related]
15. Emicizumab (Hemlibra) for subcutaneous prophylaxis in hemophilia A.
Med Lett Drugs Ther; 2019 May; 61(1572):77-79. PubMed ID: 31169801
[No Abstract] [Full Text] [Related]
16. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
Nogami K
Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
[TBL] [Abstract][Full Text] [Related]
17. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.
Müller J; Pekrul I; Pötzsch B; Berning B; Oldenburg J; Spannagl M
Thromb Haemost; 2019 Sep; 119(9):1384-1393. PubMed ID: 31203578
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for the treatment of hemophilia A and B.
Morfini M; Zanon E
Expert Opin Emerg Drugs; 2016 Sep; 21(3):301-13. PubMed ID: 27547884
[TBL] [Abstract][Full Text] [Related]
19. Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors.
Barbon E; Ayme G; Mohamadi A; Ottavi JF; Kawecki C; Casari C; Verhenne S; Marmier S; van Wittenberghe L; Charles S; Collaud F; Denis CV; Christophe OD; Mingozzi F; Lenting PJ
EMBO Mol Med; 2020 Apr; 12(4):e11298. PubMed ID: 32159286
[TBL] [Abstract][Full Text] [Related]
20. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Ragni MV
Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
